Drug treatments for people with Alzheimer’s disease should be made available on the NHS – new study finds
Published 14 July 2009
Drugs used to treat people with Alzheimer’s disease should be available on the NHS to people throughout their disease according to a new study presented at ICAD.
'The current model used by NICE to evaluate drug treatments for dementia is fundamentally flawed and must be changed. We welcome new research into finding a more accurate way of evaluating the benefits of drugs treatments for people with dementia and look forward to a new suggested model being peer reviewed and investigated further.'
Professor Clive Ballard
Director of Research
Alzheimer's Society
Ends
Reference: P3-224 - Updated Cost-Effectiveness Projections for Donepezil in the Treatment of Patients with Mild to Moderately Severe Alzheimer's Disease in the UK. Abstract.
Notes to editors
- Alzheimer's Society researchers at ICAD are available for interview or comment on request
- The International Conference on Alzheimer's Disease is held in Vienna from 11 - 16 July. Please visit ICAD for further information.
- One in three people over 65 will die with dementia
- Alzheimer's Society research shows that 700,000 people in the UK have a form of dementia, more than half have Alzheimer's disease. In less than 20 years nearly a million people will be living with dementia. This will soar to 1.7 million people by 2051.
- Alzheimer's Society champions the rights of people living with dementia and the millions of people who care for them.
- Alzheimer's Society works in England, Wales and Northern Ireland
- Alzheimer's Society needs to raise money to help people live well with
dementia today and for research to find a cure for tomorrow. You can
donate now by calling 0845 306 0898 or visiting alzheimers.org.uk
- Alzheimer's Society provides a National Dementia Helpline, the number is 0845 300 0336 or visit alzheimers.org.uk